Jefferies upgrades Zydus Life to ‘Buy’ on strong US pipeline potential, stock up 4%

August 28, 2024

Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.

More To Explore

Insurers plan performance-linked battery cover as EVs gain traction

Insurers are adapting motor insurance for electric vehicles (EVs) to address battery-related risks, a major EV cost component. Performance-linked battery failure coverage is being developed,

September 23, 2025

Sebi moves to fix ‘glitches’ in online trading platform rules

SEBI is proposing changes to the framework for technical glitches in stockbrokers’ online trading systems, excluding issues outside trading hours or beyond their control. The

September 23, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003